Divisional Patent Applications and Legal Strategies

When an examiner issues a restriction requirement, the applicant faces a tactical choice: traverse the restriction (argue it is improper) or accept it and file a divisional. Traversing requires demonstrating that the inventions are not independent or distinct, a burden that succeeds only in narrow circumstances. From a practitioner's perspective, most restriction rejections are upheld on appeal. If you believe the restriction is improper, the cost-benefit of traversal versus divisional filing must be weighed against the application's prosecution timeline and budget. Filing a divisional preserves your right to pursue the non-elected claims while maintaining priority to the original filing date.

A divisional application automatically claims priority to the parent application's filing date, provided it is filed before the parent is abandoned or issues as a patent. However, 35 U.S.C. § 121 imposes a critical deadline: a divisional must be filed while the parent is still pending. Once the parent issues or is abandoned without a pending divisional, the opportunity to claim priority is lost. In New York federal courts and the Patent Trial and Appeal Board, applicants who miss this deadline have faced dismissal of divisional applications and loss of priority rights, resulting in prior art rejections that would have been barred by an earlier priority date. Practitioners must track parent application status carefully and file divisionals proactively to avoid this trap.

One of the most common pitfalls in divisional prosecution is the introduction of new matter. Under 35 U.S.C. § 132(a), applicants cannot introduce new disclosure in a divisional that was not present in the original specification. If an examiner rejects a claim as containing new matter, the claim must be amended to align with the original disclosure, or the entire divisional application may be rejected. Amendments that broaden claim scope beyond what the original specification supports will trigger this rejection. Claim language should remain grounded in the original drawings, examples, and written description.

The parent application's prosecution history is a powerful asset. If the parent examiner allowed certain claims or made statements about claim scope, those positions constrain what the parent examiner (or a subsequent examiner reviewing the divisional) can later reject. Applicants should cite relevant Office Actions, Amendments, and Examiner Interviews from the parent to establish positions favorable to the divisional claims. This record is particularly valuable when the divisional examiner proposes rejections similar to those already addressed in the parent.

Biotech applications often require sequence listings, which are subject to specific formatting rules. When filing a divisional biotech application, the sequence listing must be identical to the parent application's sequence listing, or it will be rejected as new matter. Any update to sequences, even minor corrections, can trigger new matter objections. Practitioners must preserve the exact sequence listing from the parent and ensure consistency across all related applications.

Managing multiple related applications requires coordination across prosecution teams and jurisdictions. Divisional applications filed in the United States often have counterparts in foreign offices, and prosecution decisions in one jurisdiction may affect strategy in others. A divisional allowed in the U.S. Patent Office may support arguments for allowance in corresponding foreign applications. Conversely, rejections or amendments in foreign offices may inform divisional claim amendments. Budgeting for divisional prosecution should account for multiple filings and the long-term maintenance costs of issued patents.